Table 2 The association between of hyperbilirobimia and type 2 diabetes, gestational diabetes, and metabolic syndrome based on type of bilirubin measurements and bilirubin serum
Outcome | Variables | Categories | RR (% 95 CI) | Heterogeneity assessment | ||||
|---|---|---|---|---|---|---|---|---|
Between Studies | Between subgroup | |||||||
I square | P heterogeneity | Q | Q | P value | ||||
T2DM | Type of Bilirubin Measurements | PCB | 1.57 (1.39–1.76) | 33.90% | 0.077 | 15.49 | 38.30 | 0.0001 |
TBIL | 0.72 (0.67–0.77) | 41.58% | 0.089 | 10.09 | ||||
Bilirubin Serum (Ref. ≤0.36 mg/dl) | > 0.36 mg/dl | 0.73 (0.51–0.95) | – | – | – | 7.93 | 0.030 | |
> 0.47 mg/dl | 0.62 (0.52–0.71) | 0.00% | 0.420 | 3.87 | ||||
NR | 0.85 (0.79–0.91) | 22.82% | 0.088 | 8.09 | ||||
MetS | Type of Bilirubin Measurements | DBIL | 0.40 (0.31–0.50) | 37.06% | 0.154 | 9.53 | 12.33 | 0.0001 |
IBIL | 0.67 (0.50–0.85) | 19.77% | 0.290 | 3.74 | ||||
TBIL | 0.73 (0.70–0.76) | 56.30% | 0.066 | 13.28 | ||||
Bilirubin Serum | > 0.12 mg/dl (Ref. ≤0.12 mg/dl) | 0.75 (0.72–0.79) | 45.76% | 0.049 | 15.82 | 22.47 | 0.0001 | |
> 0.029 mg/dl (Ref. ≤0.029 mg/dl) | 0.62 (0.40–0.83) | 24.95% | 0.260 | 2.66 | ||||
> 0.10 mg/dl (Ref. ≤0.10 mg/dl) | 0.86 (0.75–0.97) | 4.07% | 0.370 | 3.13 | ||||
NR | 0.53 (0.48–0.59) | 55.44% | 0.052 | 14.80 | ||||
GDM | Type of Bilirubin Measurements | DBIL | 0.86 (0.75–0.97) | 26.40% | 0.149 | 2.17 | 0.73 | 0.700 |
IBIL | 0.91 (0.79–1.02) | 49.42% | 0.129 | 2.46 | ||||
TBIL | 0.92 (0.83–1.00) | 0.00% | 0.420 | 0.65 | ||||
Bilirubin Serum | > 0.12 mg/dl (Ref. ≤0.12 mg/dl) | 0.92 (0.84–1.00) | 0.00% | 0.420 | 0.65 | 0.37 | 0.540 | |
> 0.029 mg/dl (Ref. ≤0.029 mg/dl) | 0.88 (0.80–0.96) | 17.15% | 0.103 | 1.99 | ||||